BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32796481)

  • 1. Role of 18F-FDG PET/computed tomography in prognostication and management of malignant peripheral nerve sheath tumors.
    Yadav D; Shamim SA; Rastogi S; Upadhyay DMR; Pandey AK; Kumar R
    Nucl Med Commun; 2020 Sep; 41(9):924-932. PubMed ID: 32796481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
    Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of ¹⁸F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors.
    Khiewvan B; Macapinlac HA; Lev D; McCutcheon IE; Slopis JM; Al Sannaa G; Wei W; Chuang HH
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1756-66. PubMed ID: 24699907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
    Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
    Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
    Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors.
    Broski SM; Johnson GB; Howe BM; Nathan MA; Wenger DE; Spinner RJ; Amrami KK
    Skeletal Radiol; 2016 Aug; 45(8):1097-105. PubMed ID: 27115884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent Gastric Cancer after Curative Resection.
    Kim SH; Song BI; Kim HW; Won KS; Son YG; Ryu SW
    Korean J Radiol; 2020 Jul; 21(7):829-837. PubMed ID: 32524783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of 18F-FDG-PET/CT in management and prognostication of treatment naïve late-stage soft tissue sarcomas.
    Singh TP; Sharma A; Sharma A; Bakhshi S; Patel C; Pandey AK; Dhamija E; Batra A; Kumar R
    Nucl Med Commun; 2021 Jul; 42(7):818-825. PubMed ID: 33741856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
    Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
    Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
    Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
    Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
    Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.